Immunome, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Clay Siegall
- Full Time Employees
- 247
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18702 North Creek Parkway Bothell WA United States of America 98011
- IPO Date
- Oct 2, 2020
- CIK
- 0001472012
- Website
- immunome.com
- Similar Companies
- Business
- Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage biotechnology company developing targeted cancer therapeutics through its proprietary human memory B cell platform, which identifies novel antibodies and antigen targets for oncology applications. The company leverages this platform to discover and develop product candidates including AL102, a gamma secretase inhibitor for desmoid tumors licensed from Ayala Pharmaceuticals; QUILT-series combination immunotherapies incorporating checkpoint inhibitors, cytokines, and proprietary vaccines; and next-generation bispecific antibodies such as IMM01 targeting KLK3 and CD3 for prostate cancer and IMM02 targeting CLEVER-1 and CD3 for solid tumors. Its pipeline also encompasses MEM-01, a macropinocytosis inhibitor, and additional assets like MEM-02 and MEM-100, focusing on precision oncology for difficult-to-treat cancers; services include antibody discovery and validation for internal and partnered programs. Founded in 2006 and headquartered in Exton, Pennsylvania, Immunome operates primarily in the United States with a global focus on pharmaceutical partnerships and clinical trials across North America and Europe, targeting oncologists, cancer centers, and biopharma collaborators. Recent developments include the September 2024 acquisition of MorphImmune for $139 million, expanding its bispecific T cell engager portfolio with preclinical assets advancing toward IND filings; a December 2024 strategic collaboration with the Parker Institute for Cancer Immunotherapy to co-develop QUILT-3.072 in non-small cell lung cancer; positive interim Phase 1 data for IMM01 presented at SITC 2024 showing favorable safety and pharmacokinetics; and ongoing enrollment in the MEM-01 monotherapy and MEM-01/KEYTRUDA combination trials for pancreatic cancer, alongside preparations for a registrational trial in desmoid tumors pending FDA feedback.
Company News
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
What This Immunome Sale Means a Day Before a Big FDA Milestone
Immunome Stock Up 32% in a Month: Here's What You Should Know
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
4 Biotech Stocks Investors Should Watch in 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting